Stock vs Stock Comparison

Crinetics Pharmaceuticals, Inc. vs Eli Lilly and Company

LLY wins the Tale of the Tape 7–2.

CRNX$83.62
LLY$1216.95

🏆 Tale of the Tape

27
CRNXLLY
-6046.2%Profitability (Net Margin)31.7%
Valuation (P/E)43.1x
-39.2%Efficiency (ROIC)30.4%
2/9Health (Piotroski F)7/9
Safety (Altman Z)9.5
640.7%Growth (Rev YoY)44.7%
Risk (Sharpe 1Y)1.26
0.14xBalance Sheet (D/E)3.24x
FCF Yield0.53%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCRNXLLY
Market Cap$1.08T
P/E Ratio43.1x
Forward P/E27.3x
P/B34.77x
Dividend Yield0.57%
Beta0.51

Quantitative Metrics

MetricCRNXLLY
DCF Fair Value$292.35
DCF Upside-76.0%
Piotroski F2/97/9
Altman Z9.53
Beneish M5.75-1.91
FCF Yield0.53%
Net Debt/EBITDA1.1x
ROIC-39.2%30.4%
WACC7.9%
ROIC – WACC22.5pp
Gross Margin86.0%83.0%
Net Margin-6046.2%31.7%
Rev Growth YoY640.7%44.7%
Sharpe (1Y)1.26
Max Drawdown 3Y
FCF Payout Ratio90%

CRNX Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

CRNX found in:

XPH3.54%
VTWO0.10%
VBK0.10%
VHT0.05%

LLY found in:

XLV16.43%
IYH16.07%
VHT14.01%
ARKG4.38%
VIG3.85%
QUAL3.81%
SCHG3.17%
MGK3.07%
SPYG2.79%
IVW2.67%
VONG2.67%
IWF2.66%
VUG2.53%
QUS2.39%
XPH1.58%
SPY1.52%
ESGV1.48%
SPTM1.39%
VOO1.35%
SCHX1.34%
IVV1.30%
VTI1.29%
VONE1.28%
DGRW1.27%
SCHB1.25%
VFQY1.23%
ITOT1.15%
SPLG1.10%
DFAC1.10%
URTH0.99%
ACWI0.75%
VT0.75%
ARKK0.55%
VFMO0.46%
RSP0.18%
ONEO0.01%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CRNX vs LLY: Head-to-Head Analysis

Crinetics Pharmaceuticals, Inc. (CRNX) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 7–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CRNX generates a return on invested capital (ROIC) of -39.2% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

CRNX appears in 4 ETFs tracked by SecuritiesDB, while LLY appears in 36 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CRNX or LLY?

Our quantitative analysis compares CRNX and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 7–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CRNX and LLY correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.